Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 4
1976 36
1977 26
1978 69
1979 131
1980 87
1981 88
1982 112
1983 124
1984 84
1985 89
1986 78
1987 102
1988 106
1989 104
1990 91
1991 87
1992 62
1993 65
1994 44
1995 35
1996 25
1997 20
1998 28
1999 31
2000 35
2001 26
2002 26
2003 21
2004 31
2005 26
2006 36
2007 31
2008 48
2009 44
2010 42
2011 52
2012 53
2013 46
2014 54
2015 60
2016 57
2017 58
2018 50
2019 60
2020 67
2021 55
2022 64
2023 71
2024 81
2025 29

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,821 results

Results by year

Filters applied: . Clear all
Page 1
Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects.
MacCarthy EP, Bloomfield SS. MacCarthy EP, et al. Pharmacotherapy. 1983 Jul-Aug;3(4):193-219. doi: 10.1002/j.1875-9114.1983.tb03252.x. Pharmacotherapy. 1983. PMID: 6310529 Review.
Labetalol is a combined alpha- and beta-adrenoceptor blocking agent for oral and intravenous use in the treatment of hypertension. ...In addition, preliminary studies indicate that labetalol may be of value in the management of ischemic heart disease. The most troub …
Labetalol is a combined alpha- and beta-adrenoceptor blocking agent for oral and intravenous use in the treatment of hypertension. .. …
Pregnancy Outcomes of Nifedipine Compared With Labetalol for Oral Treatment of Mild Chronic Hypertension.
Sanusi AA, Leach J, Boggess K, Dugoff L, Sibai B, Lawrence K, Hughes BL, Bell J, Aagaard K, Edwards RK, Gibson KS, Haas DM, Plante L, Metz TD, Casey B, Esplin S, Longo S, Hoffman MK, Saade GR, Hoppe KK, Foroutan J, Tuuli M, Owens MY, Simhan HN, Frey H, Rosen T, Palatnik A, Baker S, August P, Reddy UM, Su EJ, Krishna I, Nguyen NA, Norton ME, Skupski D, El-Sayed YY, Ogunyemi D, Galis ZS, Harper L, Ambalavanan N, Geller NL, Kuo HC, Sinkey RG, Librizzi R, Pereira L, Magann EF, Habli M, Williams S, Mari G, Pridjian G, McKenna DS, Parrish M, Eugene Chang, Osmundson S, Quinones J, Szychowski JM, Tita ATN. Sanusi AA, et al. Obstet Gynecol. 2024 Jul 1;144(1):126-134. doi: 10.1097/AOG.0000000000005613. Epub 2024 May 23. Obstet Gynecol. 2024. PMID: 38949541 Clinical Trial.
We performed three comparisons based on medications prescribed at enrollment: labetalol compared with standard care, nifedipine compared with standard care, and labetalol compared with nifedipine. ...The primary outcome occurred in 217 (30.1%), 130 (31.2%), and 427 …
We performed three comparisons based on medications prescribed at enrollment: labetalol compared with standard care, nifedipine compa …
Labetalol.
Carter BL. Carter BL. Drug Intell Clin Pharm. 1983 Oct;17(10):704-12. Drug Intell Clin Pharm. 1983. PMID: 6354658 Review.
Labetalol is a competitive antagonist of alpha 1-, beta 1-, and beta 2-adrenergic receptors. ...Reductions in heart rate are less pronounced with labetalol as compared with propranolol. Labetalol produces rapid reductions in blood pressure when administered i …
Labetalol is a competitive antagonist of alpha 1-, beta 1-, and beta 2-adrenergic receptors. ...Reductions in heart rate are less pro …
Labetalol hepatotoxicity.
Chon EM, Middleton RK. Chon EM, et al. Ann Pharmacother. 1992 Mar;26(3):344-5. Ann Pharmacother. 1992. PMID: 1554954 No abstract available.
Labetalol Dosing in Pregnancy: PBPK/PD and CYP2C19 Polymorphisms.
Liu XI, Green DJ, van den Anker J, Calderon J, Ahmadzia H, Burckart GJ, Dallmann A. Liu XI, et al. J Clin Pharmacol. 2024 Nov;64(11):1443-1455. doi: 10.1002/jcph.2496. Epub 2024 Jul 8. J Clin Pharmacol. 2024. PMID: 38973651
As detailed information on the pharmacokinetics (PK) of labetalol in pregnant people are lacking, the aims of this study were: (1) to build a physiologically based PK (PBPK) model of labetalol in non-pregnant individuals that incorporates different CYP2C19 genotypes …
As detailed information on the pharmacokinetics (PK) of labetalol in pregnant people are lacking, the aims of this study were: (1) to …
Labetalol in hypertension.
[No authors listed] [No authors listed] Lancet. 1977 Apr 23;1(8017):890-1. Lancet. 1977. PMID: 67294 No abstract available.
Pharmacological effects of labetalol in man.
Richards DA. Richards DA. Br J Clin Pharmacol. 1976 Aug;3(4 Suppl 3):721-3. Br J Clin Pharmacol. 1976. PMID: 10949 Free article. Review.
1 The pharmacological effects of labetalol have been studied in normal healthy subjects. The results of these studies are reviewed. 2 In the evaluation of the beta-adrenoreceptor-blocking effects of labetalol various indices of beta-adrenoceptor blockade in man were …
1 The pharmacological effects of labetalol have been studied in normal healthy subjects. The results of these studies are reviewed. 2 …
Labetalol hepatotoxicity.
Thiele DL. Thiele DL. Am J Med. 1989 Sep;87(3):361. doi: 10.1016/s0002-9343(89)80173-1. Am J Med. 1989. PMID: 2773977 No abstract available.
Labetalol hepatotoxicity.
[No authors listed] [No authors listed] Ann Intern Med. 1991 Feb 15;114(4):341. doi: 10.7326/0003-4819-114-4-341. Ann Intern Med. 1991. PMID: 2018583 No abstract available.
Treatment of Post-Coarctectomy Hypertension With Labetalol-A 9-Year Single-Center Experience.
Siersma C, Brouwer CNM, Sojak V, Ten Harkel ADJ, Roeleveld PP. Siersma C, et al. World J Pediatr Congenit Heart Surg. 2022 Nov;13(6):701-706. doi: 10.1177/21501351221111797. World J Pediatr Congenit Heart Surg. 2022. PMID: 36300272 Free PMC article.
RESULTS: 96 patients were included, 45 were treated with intravenous labetalol and 51 received no treatment. Median time to maximum dose received (median 1.1 mg/kg/h) was 2.7 h, and median time to the reduction of labetalol dose was 8.3 h. No antihypertensives had t …
RESULTS: 96 patients were included, 45 were treated with intravenous labetalol and 51 received no treatment. Median time to maximum d …
2,821 results